ArticlemBio2020
The Unrecognized Threat of Secondary Bacterial Infections with COVID-19.
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed.
- Single-cell transcriptomic atlas uncovers immune/structural lineage remodeling and fibrosis inVirulence · 2026Article
- Co-infection models ofFrontiers in cellular and infection microbiology · 2026Article
- Impacts of adipokines in the development and consequence of COVID-19-associated mucormycosis.Archives of microbiology · 2025Article
- Phagetherapy updates: New frontiers against antibiotic resistance.European journal of microbiology & immunology · 2025Review
- Impact of healthcare-associated infections on in-hospital outcomes during the COVID-19 era: a multicenter comparative study of 20,942 isolated microorganisms from ICU patients.Frontiers in public health · 2025Article
- Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance.Heliyon · 2024Review
- Synergistic effects of COVID-19 and Pseudomonas aeruginosa in chronic obstructive pulmonary disease: a polymicrobial perspective.Molecular and cellular biochemistry · 2024Review
- Secondary and Co-Infections in Hospitalized COVID-19 Patients: A Multicenter Cross-Sectional Study in Malaysia.Antibiotics (Basel, Switzerland) · 2023Article
- One Earth: The Equilibrium between the Human and the Bacterial Worlds.International journal of molecular sciences · 2023Review
- Investigation of microbial coinfection in 453 septic COVID-19 patients admitted to hospital; a retrospective study.Future science OA · 2023Article
- Multi-pathogen based chimeric vaccine to fight against COVID-19 and concomitant coinfections.Biotechnology letters · 2023Article
- Stable Superhydrophobic and Antimicrobial ZnO/Polytetrafluoroethylene Films via Radio Frequency (RF) Magnetron Sputtering.Micromachines · 2023Article
- Article
- Article
- Development of lipidated polycarbonates with broad-spectrum antimicrobial activity.Biomaterials science · 2023Article
- Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients.Microorganisms · 2023Review
- Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells.Inflammopharmacology · 2023Review
- An Overview of the Impact of Bacterial Infections and the Associated Mortality Predictors in Patients with COVID-19 Admitted to a Tertiary Center from Eastern Europe.Antibiotics (Basel, Switzerland) · 2023Article
- The under investigated facet of the COVID-19 pandemic: Molecular analysis of secondary bacterial infections at a COVID dedicated intensive care unit within a tertiary care center in Lebanon.Frontiers in medicine · 2023Article
- The Potential Nexus between Helminths and SARS-CoV-2 Infection: A Literature Review.Journal of immunology research · 2023Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) is the greatest pandemic of our generation, with 16 million people affected and 650,000 deaths worldwide so far. One of the risk factors associated with COVID-19 is secondary bacterial pneumonia. In recent studies on COVID-19 patients, secondary bacterial infections were significantly associated with worse outcomes and death despite antimicrobial therapies. In the past, the intensive use of antibiotics during the severe acute respiratory syndrome coronavirus (SARS-CoV) pandemic led to increases in the prevalence of multidrug-resistant bacteria. The rising number of antibiotic-resistant bacteria and our decreasing capacity to eradicate them not only render us more vulnerable to bacterial infections but also weaken us during viral pandemics. The COVID-19 pandemic reminds us of the great health challenges we are facing, especially regarding antibiotic-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.